---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-108344"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:45:47.364416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atara reports FY 2025 net income of $32.7M; cash runway extended through YE 2026

## Summary
- Net income of $32.7M ($2.61 per share) in FY 2025 vs. net loss of $85.4M in FY 2024.
- Cash, equivalents and investments $8.5M at Dec 31, 2025; net cash used in ops $50.9M in FY 2025.
- Operating expenses declined sharply; expects cash plus $3.0M ATM proceeds to fund ops through YE 2026.
- Pierr Fabre scheduled FDA Type A meeting for tab-cel PTLD; regulatory update expected in Q2 2026.
- Milestone payment of $9.0M due to HCRx deferred from June 2026 to Jan 2028; warrant issued for 400K shares.

## SEC filing metadata
- accession: 0001193125-26-108344
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-108344
- JSON: https://secwatch.observer/filing/0001193125-26-108344.json
- Plain text: https://secwatch.observer/filing/0001193125-26-108344.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported the fiscal year ended December 31, 2025 results: revenue $120.8 million, net income $32.7 million, EPS $2.61 per share. Guidance initiated.
  - Period: the fiscal year ended December 31, 2025
  - Revenue: $120.8 million
  - Net income: $32.7 million
  - EPS: $2.61 per share
  - Guidance: initiated
  - Result: reported results
  source text: as compared to a net loss of ($12.7) million, or ($1.19) per share, and ($85.4) million, or ($11.41) per share, for the same periods in 2024. ● Commercialization revenues were $120.8 million in 2025 as compared to $128.9 million in 2024. ● Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $1.6
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm
- Earnings Releases
  Atara Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income ($3.4) million, EPS ($0.25) per share. Guidance initiated.
  - Period: the fourth quarter ended December 31, 2025
  - Net income: ($3.4) million
  - EPS: ($0.25) per share
  - Guidance: initiated
  - Result: reported results
  source text: Atara reported a net loss of ($3.4) million, or ($0.25) per share, and a net income of $32.7 million, or $2.61 per share, for the fourth quarter and fiscal year 2025, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.